| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 1B | -1% |
| Operating Income | 132.9MM | -12% |
| Operating Expenses | 880.6MM | - |
| Net Income | 187.1MM | - |
| G&A | 197.1MM | +12% |
| Amortization | 34MM | -1% |
| Interest Expense | 33.5MM | -1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
WILMINGTON, Mass., April 22, 2024--In addition to advancing human health and improving quality of life, we are dedicated to a responsible tomorrow.
Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.
WILMINGTON, Mass., April 16, 2024--Charles River launches the Alternative Methods Advancement Project (AMAP), an initiative to develop alternatives to reduce animal testing.
ICLR vs. CRL: Which Stock Is the Better Value Option?
WILMINGTON, Mass., April 12, 2024--Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 9th, at 8:30 a.m. ET.
Charles River (CRL) is set to perform plasmid production for Ship of Theseus.
WILMINGTON, Mass. & DUBLIN, April 11, 2024--Charles River and Deciphex launch Patholytix Foresight, an AI-powered decision support tool for toxicologic pathology.
WILMINGTON, Mass., April 09, 2024--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd. Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure.